| MYELODYSPLASTIC SYNDROME
Tibsovo vs Reblozyl
Side-by-side clinical, coverage, and cost comparison for myelodysplastic syndrome.Deep comparison between: Tibsovo vs Reblozyl with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsReblozyl has a higher rate of injection site reactions vs Tibsovo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Reblozyl but not Tibsovo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tibsovo
Reblozyl
At A Glance
Oral
Daily
IDH1 inhibitor
SC injection
Every 3 weeks
Erythroid maturation agent
Indications
- Leukemia, Myelocytic, Acute
- MYELODYSPLASTIC SYNDROME
- Cholangiocarcinoma
- beta Thalassemia
- MYELODYSPLASTIC SYNDROME
- Refractory anemia with ringed sideroblasts
- Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis
Dosing
Leukemia, Myelocytic, Acute 500 mg orally once daily; newly diagnosed: in combination with azacitidine 75 mg/m2 SC or IV on Days 1-7 of each 28-day cycle, or as monotherapy, for minimum 6 months; relapsed/refractory: monotherapy until disease progression or unacceptable toxicity.
MYELODYSPLASTIC SYNDROME 500 mg orally once daily as monotherapy until disease progression or unacceptable toxicity; continue for minimum 6 months.
Cholangiocarcinoma 500 mg orally once daily until disease progression or unacceptable toxicity.
beta Thalassemia 1 mg/kg SC every 3 weeks; increase to max 1.25 mg/kg if no reduction in RBC transfusion burden after at least 2 consecutive doses at 1 mg/kg.
MYELODYSPLASTIC SYNDROME (ESA-naive) 1 mg/kg SC every 3 weeks; increase up to max 1.75 mg/kg to maintain hemoglobin 10 g/dL to 12 g/dL.
Refractory anemia with ringed sideroblasts, Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (ESA-refractory or intolerant) 1 mg/kg SC every 3 weeks; increase to max 1.75 mg/kg if patient is not RBC transfusion-free.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) leukocytes decreased, diarrhea, hemoglobin decreased, platelets decreased, glucose increased, fatigue, alkaline phosphatase increased, edema, potassium decreased, nausea, vomiting, phosphatase decreased, decreased appetite, sodium decreased, leukocytosis, magnesium decreased, aspartate aminotransferase increased, arthralgia, dyspnea, uric acid increased, abdominal pain, creatinine increased, mucositis, rash, electrocardiogram QT prolonged, differentiation syndrome, calcium decreased, neutrophils decreased, myalgia
Serious differentiation syndrome, electrocardiogram QT prolonged, leukocytosis, Guillain-Barre syndrome
Most common (>=10%) headache, bone pain, arthralgia, fatigue, cough, abdominal pain, diarrhea, dizziness, hypertension, nausea, edema peripheral, dyspnea, musculoskeletal pain
Serious thrombosis/thromboembolism, hypertension, extramedullary hematopoietic masses, cerebrovascular accident, deep vein thrombosis
Pharmacology
Ivosidenib is a small molecule inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme that reduces 2-hydroxyglutarate (2-HG) levels and induces myeloid differentiation in IDH1-mutated AML; in IDH1-mutated cholangiocarcinoma, it also reduces 2-HG levels in tumor tissue.
Luspatercept-aamt is a recombinant fusion protein that binds several endogenous TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling and promoting erythroid maturation by increasing late-stage erythroid precursors (normoblasts) to reduce ineffective erythropoiesis in beta-thalassemia and MDS.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tibsovo
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (4/12) · Qty limit (12/12)
Reblozyl
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Tibsovo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Reblozyl
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Tibsovo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Reblozyl
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Tibsovo.
Cost estimate not availableAccessia Health: Myelodysplastic Syndromes - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TibsovoView full Tibsovo profile
ReblozylView full Reblozyl profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.